Inicio>>Signaling Pathways>> Stem Cell>> Wnt/β-catenin>>Carboxylesterase-IN-3

Carboxylesterase-IN-3

Catalog No.GC65167

La carboxilesterasa-IN-3 (compuesto 4y) es un potente inhibidor de la carboxilesterasa Notum con una IC50 inferior o igual a 10 nM. Notum es un regulador negativo de la seÑalizaciÓn de Wnt que actÚa a través de la hidrÓlisis de un éster de palmitoleoylato, que se requiere para la actividad de Wnt. La carboxilesterasa-IN-3 tiene el potencial para la investigaciÓn de la enfermedad del cÁncer.

Products are for research use only. Not for human use. We do not sell to patients.

Carboxylesterase-IN-3 Chemical Structure

Cas No.: 2764748-92-5

Tamaño Precio Disponibilidad Cantidad
5mg
270,00 $
Disponible
10mg
432,00 $
Disponible
25mg
855,00 $
Disponible
50mg
1.305,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Carboxylesterase-IN-3 (compound 4y) is a potent inhibitor of Carboxylesterase Notum with an IC50 less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Carboxylesterase-IN-3 has the potential for the research of cancer disease[1].

[1]. Steadman D, et al. Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity. J Med Chem. 2022;65(1):562-578.

Reseñas

Review for Carboxylesterase-IN-3

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carboxylesterase-IN-3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.